NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I think she is talking about going forward, not specifically to her trial, but as they learn the pathology of the disease and how it responds to various treatments, they are learning that there could be a particular order to using the drugs, there could be ways to follow the biomarkers that tell them when to administer certain drugs to address each stage if the immune reaction to the previously administered drug.

Minutes before that statement explain quite clearly what she means. It is a complex disease and I believe she basically means they can increase efficacy and validate their science, all the things they know are happening, with better tools and a more adaptive and dynamic framework to the clinical trials. This specifically probably addresses that they know a lot more than the static structure of trials allows them to do to address the patient’s physical responses to both the tumor and any one single drug. I think it is clear that the science itself is far more advanced than the current structure of trials allows and they probably need to slow for a focus in biomarkers, and if then opportunities to address particular symptoms / biomarkers with additional agents, where appropriate. This must be particularly true where there is so much variation to the individual tumors.